Granules India Ltd

- In the Q3 FY26 earnings call, Granules India Limited recently completed a **preferential equity issue** with strong shareholder support, enhancing financial flexibility. - The proceeds from this preferential issue are intended to support **capacity expansion, drive efficiency, and pursue value-accretive opportunities**, while maintaining capital discipline. - There was no mention of any **imminent or future fundraising through debt** during the call. - The company emphasized prudent deployment of the preferential issue proceeds rather than announcing new debt or equity raises.

- Granules is investing in system enhancements involving capex and opex over upcoming quarters to strengthen operational reliability and resilience. - Expansion plans include capacity expansion supported by proceeds from a recent preferential issue aimed at enhancing financial flexibility. - New plants, including an API plant in Vizag with advanced automation (DCS-driven, paperless documentation), are under development. - Continued focus on digitalization and automation, especially at Gagillapur (implementation expected by mid-calendar year), to improve quality and compliance. - Investment will also support scaling operations at GLS facility as regulatory milestones are achieved. - Ongoing investments in R&D to support long-term strategic growth, sustaining 5% of sales in R&D expenses. - Strategic capital employed prudently to pursue value-accretive opportunities while maintaining governance and capital discipline.

- Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years. - Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected. - Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues. - Growth in the U.S. market via early generic launches for limited competition products like lisdexamfetamine and generic Adzenys with significant market share potential. - Steady expansion supported by operational efficiencies and increased capacity utilization at Gagillapur and GLS sites. - Expected sequential improvement in sales and margins in core and new products, including ramp-up in peptide and CRAMS business. - Long-term aspiration to add $40-50 million annually to U.S. revenues, reflecting strong growth trajectory.

- Granules India expects meaningful growth from 3-4 product launches within the next 1 to 1.5 years, particularly in complex generics like CNS, ADHD, and controlled substances. - Controlled substances such as amphetamine are strategically important, likely contributing significantly to earnings due to limited competition and early market entry. - Expansion and approvals at the Genome Valley facility will drive incremental revenue in FY27, with 1-2 product launches expected in the next two quarters. - The company aims for steady EBITDA margin improvement through an increased share of complex generics and formulation sales mix. - Operational efficiencies and capacity utilization improvements, especially post-remediation at Gagillapur and scaling at GLS, will support earnings growth. - The peptide CDMO business is expected to improve to breakeven and positive EBITDA in Q4 FY26, contributing positively going forward. - The management is confident of adding $40-50 million to US revenues annually in coming years, supporting growth.

The transcript does not explicitly provide details on the current or expected order book or pending orders for Granules India Limited. However, related insights can be summarized as follows: - The CDMO (Contract Development and Manufacturing Organization) business is activity intense with project executions progressing; improvement and increased order execution are expected in Q4 FY '26. - Several key customer deliveries are scheduled in Q4. - Multiple product launches (3 to 4) are planned within the next 1 to 1.5 years, indicating an expanding pipeline. - Regulatory approvals and site transfers (e.g., European approval pending for Genome Valley facility) will enable increased commercial execution. - The company is strengthening its market presence and scaling operations in key geographies, suggesting growing demand. No specific quantitative order book or pending order figures are mentioned in the material.